Sparrow BioAcoustics is a Canadian medical-technology company that has developed Stethophone, the first FDA-cleared cardiac AI platform able to detect structural and rhythmic heart anomalies directly through a smartphone without external hardware. The system employs AI phonoscopy to identify murmurs, valvular disease, atrial fibrillation, and other conditions, delivering hospital-grade assessments with consumer-grade accessibility. In the past year, approximately 40,000 patients and practitioners used Stethophone, uncovering thousands of previously undetected cardiac anomalies. Clinical validation from the University of Washington Medical Center confirmed high accuracy in detecting valvular disease and atrial fibrillation, and additional evaluations are underway at several major U.S. and Canadian sites. The company is actively showcasing the product at leading cardiology conferences such as TCT and the American Heart Association Scientific Sessions. Fresh capital is earmarked to scale U.S. hospital deployments, sustain product momentum, and support growth initiatives. The recent $10 million raise marks a key milestone in financing Sparrow’s expansion and continued R&D efforts.

Total raised

$23M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025